Show Summary Details
Page of

Medical management of diabetic retinopathy 

Medical management of diabetic retinopathy
Medical management of diabetic retinopathy
Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 03 August 2020

Medical management is focused on the proven benefit of tight glucose and blood pressure control.

Standard management includes multiple cardiovascular risk factor management with angiotensin receptor blockade, statin and fibrate treatment in addition to aspirin.

Targets to achieve include HbA1c <7%, blood pressure <140/80, and serum cholesterol <4mmol/l.

A number of new trials have demonstrated the beneficial effects on diabetic retinopathy (DR) of fenofibrate (lipid lowering), and Ruboxistaurin ® (protein kinase C inhibition) with reduction of laser treatment and protection of vision.

A landmark study of an angiotensin receptor blocker is due to complete shortly (DIRECT study) which will provide data on the potential benefit of this treatment on both primary and secondary prevention of DR.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.